Analyst Breaks Down Bluebird Bio's Better-Than-Expected Clinical Results
December 01, 2016 at 13:33 PM EST
Wedbush analyst David Nierengarten maintains his Outperform rating and $95 target price on bluebird bio Inc (NASDAQ: BLUE), which ...